Cancer of the renal pelvis or ureter is cancer that forms in the kidney's pelvis or the tube that carries urine from the kidney to the bladder.
Transitional cell cancer of the renal pelvis or ureter
Causes, incidence, and risk factors
Cancer can grow in the urine collection system, but is uncommon. As a group, renal pelvis and ureter cancers account for about 5% of all cancers of the kidney and upper urinary tract. They affect men more often than women and are more common in people older than 65.
Tumors of the renal pelvis and ureter are usually transitional cell cancers. Approximately 10% are squamous cell carcinomas.
The causes of this cancer are not completely known. Long-term (chronic) irritation of the kidney from harmful substances removed in the urine may be a factor. This irritation may be caused by:
These tests may reveal a tumor or show that the cancer has spread from the kidneys.
The goal of treatment is to eliminate the cancer.
Surgery to remove all or part of the kidney (nephrectomy) is usually recommended. This may include removing part of the bladder and tissues around it, or the lymph nodes. If the tumor is in the ureter, it may be possible to remove it while preserving the kidney.
When the cancer has spread outside of the kidney or ureter, chemotherapy is often used. Because these tumors are similar to a form of bladder cancer, they are treated with a similar type of chemotherapy.
Call your health care provider if you have the symptoms listed above.
Follow your health care provider's advice regarding medications, including over-the-counter pain medicine.
Wear protective equipment if you may be exposed to substances that are toxic to the kidneys.
Bajorin DF. Tumors of the kidney, bladder, ureters, and renal pelvis. In Goldman L, Schafer AI, eds. Cecil Medicine. 24th ed. Philadelphia, PA: Saunders Elsevier; 2011:chap 203.
National Comprehensive Cancer Network. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology: Bladder cancer. 2012. Version 2.2012.
David C. Dugdale, III, MD, Professor of Medicine, Division of General Medicine, Department of Medicine, University of Washington School of Medicine; Yi-Bin Chen, MD, Leukemia/Bone Marrow Transplant Program, Massachusetts General Hospital. Also reviewed by David Zieve, MD, MHA, Medical Director, A.D.A.M., Inc.